Endocrinol Metab.  2014 Jun;29(2):206-207. 10.3803/EnM.2014.29.2.206.

Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.)

• Jung CH

• KMID: 2169429
• DOI: http://doi.org/10.3803/EnM.2014.29.2.206

Abstract

No abstract available.

MeSH Terms

Humans
Thyroid Neoplasms*

Reference

1. Robbins RJ, Chon JT, Fleisher M, Larson SM, Tuttle RM. Is the serum thyroglobulin response to recombinant human thyrotropin sufficient, by itself, to monitor for residual thyroid carcinoma? J Clin Endocrinol Metab. 2002; 87:3242–3247.

2. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009; 19:1167–1214.

3. Jeon EJ, Jung ED. Diagnostic whole-body scan may not be necessary for intermediate-risk patients with differentiated thyroid cancer after low-dose (30 mCi) radioactive iodide ablation. Endocrinol Metab (Seoul). 2014; 29:33–39.